

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 27/00, C08F 220/30, G02B 1/04	A1	(11) International Publication Number: WO 96/40303 (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/06743 (22) International Filing Date: 10 May 1996 (10.05.96) (30) Priority Data: 08/486,557 7 June 1995 (07.06.95) US (71) Applicant: ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Fort Worth, TX 76134-2099 (US). (72) Inventors: FREEMAN, Charles; 725 Windridge Lane, Burleson, TX 76028 (US). JINKERSON, David, L.; 125 Berkshire Lane, Fort Worth, TX 76134 (US). KARAKELLE, Mutlu; 6713 Glen Meadow Drive, Fort Worth, TX 76132 (US). LeBOEUF, Albert, R.; 7861 Mahonia Drive, Fort Worth, TX 76133 (US). (74) Agents: RYAN, Patrick, M. et al.; Alcon Laboratories, Inc., Patent Dept. Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).	(81) Designated States: AU, CA, CN, JP, KR, MX, SG, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: IMPROVED HIGH REFRACTIVE INDEX OPHTHALMIC LENS MATERIALS (57) Abstract Disclosed are improved soft, high refractive index, acrylic materials having an elongation of at least 150 %. These materials, especially useful as intraocular lens materials, contain two principal monomers: an aryl acrylic hydrophobic monomer and a hydrophilic monomer.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

IMPROVED HIGH REFRACTIVE INDEX OPHTHALMIC

LENS MATERIALS

5

Field of the Invention

This invention is directed to improved ophthalmic lens materials. In particular, this
10 invention relates to soft, high refractive index ophthalmic lens materials particularly suited
for use as intraocular lens ("IOL") materials.

Background of the Invention

15 With the recent advances in small-incision cataract surgery, increased emphasis has
been placed on developing soft, foldable materials suitable for use in artificial lenses. In
general, these materials fall into one of three categories: hydrogels, silicones, and acrylics.

In general, hydrogel materials have a relatively low refractive index, making them
20 less desirable than other materials because of the thicker lens optic necessary to achieve a
given refractive power. Silicone materials generally have a higher refractive index than
hydrogels, but tend to unfold explosively after being placed in the eye in a folded position.
Explosive unfolding can potentially damage the corneal endothelium and/or rupture the
natural lens capsule. Acrylic materials are desirable because they typically have a high
25 refractive index and unfold more slowly or controllably than silicone materials.

U.S. Patent No. 5,290,892 discloses high refractive index, acrylic materials suitable
for use as an IOL material. These acrylic materials contain, as principal components, two
aryl acrylic monomers. The IOLs made of these acrylic materials can be rolled or folded
30 for insertion through small incisions.

U.S. Patent No. 5,331,073 also discloses soft acrylic IOL materials. These
materials contain as principal components, two acrylic monomers which are defined by the
properties of their respective homopolymers. The first monomer is defined as one in
35 which its homopolymer has a refractive index of at least about 1.50. The second monomer

is defined as one in which its homopolymer has a glass transition temperature less than about 22 °C. These IOL materials also contain a cross-linking component. Additionally, these materials may optionally contain a fourth constituent, different from the first three constituents, which is derived from a hydrophilic monomer. These materials preferably
5 have a total of less than about 15% by weight of a hydrophilic component.

Summary of the Invention

Improved soft, foldable acrylic lens materials which are particularly suited for use
10 as IOLs, but which are also useful as other ophthalmic devices, such as contact lenses, keratoprotheses, and corneal rings or inlays, have now been discovered. These materials contain only two principal components: one aryl acrylic hydrophobic monomer and one hydrophilic monomer. The materials of the present invention are copolymers comprising at least about 90% by weight of the two principal monomeric components; provided that
15 the amount of the hydrophilic component is not greater than that of the aryl acrylic hydrophobic component. The remainder of the material comprises up to 10% by weight of one or more additional components, such as cross-linking, UV-light absorbing, and blue-light absorbing components.


20 Among other factors, the present invention is based on the finding that acrylic copolymers suitable for use as foldable IOL materials can be synthesized using only one principal acrylic hydrophobic monomer and one principal hydrophilic monomer.

Among other factors, the present invention is also based on the finding that, unlike
25 other acrylic copolymers useful as IOL materials, the copolymers of the present invention are substantially free of glistenings in a physiologic environment.

Detailed Description of the Invention

30 The improved acrylic materials of the present invention are copolymers comprising only two principal monomeric components: an aryl acrylic hydrophobic component and a hydrophilic component.

The aryl acrylic hydrophobic monomers suitable for use in the materials of the present invention have the formula



wherein: X is H or CH₃ ;

m is 0-6;

Y is nothing, O, S, or NR, wherein R is H, CH₃, C_nH_{2n+1} (n=1-10), iso-OC₃H₇, C₆H₅, or CH₂C₆H₅; and

Ar is any aromatic ring which can be unsubstituted or substituted with H, CH₃, C₂H₅, n-C₃H₇, iso-C₃H₇, OCH₃, C₆H₁₁, Cl, Br, C₆H₅, or CH₂C₆H₅.

Monomers of the above structural formula are described in US 5,290,892, the entire contents of which are hereby incorporated by reference. Preferred aryl acrylic hydrophobic monomers for use in the materials of the present invention are those wherein m is 2 - 4, Y is nothing or O, and Ar is phenyl. Most preferred are 2-phenylethyl acrylate and 4-phenylbutyl methacrylate.

The homopolymers of the aryl acrylic hydrophobic monomers suitable for use in the present invention contain an equilibrium water content of less than 3 %, and preferably less than 2 %, by weight as determined gravimetrically in deionized water at ambient conditions.

The hydrophilic monomers suitable for use in the present invention contain at least one reactive, unsaturated functional group. Preferably, the reactive unsaturated functional group is a vinyl, acrylate or methacrylate group.

The homopolymers of the hydrophilic monomers suitable for use in the materials of the present invention have an equilibrium water content of at least 10 %, and preferably

at least 25 %, by weight as determined gravimetrically in deionized water at ambient conditions.

Suitable hydrophilic monomers for use in the present invention include 2-
5 hydroxyethyl acrylate; 2-hydroxyethyl methacrylate; 2-N-ethylacrylate pyrrolidone; 2-
hydroxy-3-phenoxypropyl acrylate; 2,3-dihydroxypropyl acrylate; 2,3-dihydroxypropyl
methacrylate; 2-N-vinyl pyrrolidone; polyethylene oxide:200 monomethyl ether
monomethacrylate; polyethylene oxide:200 monomethacrylate; polyethylene oxide:1000
dimethacrylate.

10

Preferred hydrophilic monomers for use in the present invention are include 2-
hydroxyethyl acrylate; 2-hydroxyethyl methacrylate; and polyethylene oxide:1000
dimethacrylate.

15

The materials of the present invention are copolymers comprising a total of about
90 % by weight of the two principal components described above, provided that the
amount of the hydrophilic component is not greater than the aryl acrylic hydrophobic
component.

20

The copolymer materials of the present invention are cross-linked. The
copolymerizable cross-linking agent used in the copolymers of this invention may be any
terminally ethylenically unsaturated compound having more than one unsaturated group.
Combinations of cross-linking monomers are also suitable. Suitable cross-linking agents
include, for example: ethylene glycol dimethacrylate, diethylene glycol dimethacrylate,
25 allyl methacrylate, 1,3-propanediol dimethacrylate, allyl methacrylate, 1,6-hexanediol
dimethacrylate, 1,4-butanediol dimethacrylate, and the like. A preferred cross-linking
agent is 1,4-butanediol diacrylate (BDDA). Generally, the amount of the cross-linking
component is at least 0.1 % (weight).

30

In addition to an aryl acrylic hydrophobic monomer, a hydrophilic monomer, and one
or more cross-linking components, the lens material of the present invention may also

contain a total of up to about 10 % by weight of additional components which serve other purposes, such as polymerization initiators and reactive UV and/or blue-light absorbers.

Preferred polymerization initiators are peroxy free-radical initiators, such as t-butyl
5 (peroxy-2-ethyl)hexanoate and di-(tert-butylcyclohexyl) peroxydicarbonate (commercially available as Perkadox[®] 16 from Akzo Chemicals Inc., Chicago, Illinois). Initiators are typically present in an amount of about 5 % (weight) or less.

A preferred reactive UV absorber is 2-(2'-hydroxy-3'-methallyl-5'-
10 methylphenyl)benzotriazole, commercially available as o-Methallyl Tinuvin P ("oMTP") from Polysciences, Inc., Warrington, Pennsylvania. UV absorbers are typically present in an amount from about 0.1 - 5 % (weight).

Suitable reactive blue-light absorbing compounds are those described in commonly
15 assigned, copending U.S. patent application serial number 08/138,663, the entire contents of which are hereby incorporated by reference. Blue-light absorbers are typically present in an amount from about 0.01 - 0.5 % (weight).

The particular combination of the two principal monomers described above and the
20 identity and amount of any additional components are determined by the desired properties of the finished ophthalmic lens. Preferably, the ingredients and their proportion are selected so that the improved acrylic lens materials of the present invention possess the following properties, which make the materials of the present invention particularly suitable for use in IOLs which are to be inserted through incisions of 5 mm or less.

25 The lens material preferably has a refractive index of at least about 1.50 as measured by an Abbe' refractometer at 589 nm (Na light source). Optics made from materials having a refractive index lower than 1.50 are necessarily thicker than optics of the same power which are made from materials having a higher refractive index. As such, IOL optics made from
30 materials having a refractive index lower than about 1.50 generally require relatively larger incisions for IOL implantation.

The glass-transition temperature ("T_g") of the lens material, which affects the material's folding and unfolding characteristics, is preferably between about -20 to +25 °C, and more preferably between about -5 and +16 °C. T_g is measured by differential scanning calorimetry at 10 °C/min., and is determined at the midpoint of the transition of the heat flux curve.

The lens material will have an elongation of at least 150%, preferably at least 200%, and most preferably between 300 and 600%. This property indicates that the lens generally will not crack, tear or split when folded. Elongation of polymer samples is determined on dumbbell shaped tension test specimens with a 20 mm total length, length in the grip area of 4.88 mm, overall width of 2.49 mm, 0.833 mm width of the narrow section, a fillet radius of 8.83 mm, and a thickness of 0.9 mm. Testing is performed on samples at standard laboratory conditions of 23 ± 2 °C and 50 ± 5 % relative humidity using an Instron Material Tester model 1122 with a 2000 gram load cell. The grip distance is set at 14 mm and a crosshead speed is set at 20 mm/minute and the sample is pulled to 700 % elongation or until failure. The elongation (strain) is reported as a fraction of the displacement at failure to the original grip distance. The modulus is calculated as the instantaneous slope of the stress-strain curve at 100 % strain. Stress is calculated at the maximum load for the sample, typically the load when the sample breaks.

The lens materials of the present invention are substantially free of glistenings in a physiologic environment. Glistenings are the result of condensation of water vapor within the lens. Although glistenings have no detrimental effect on the function or performance of IOLs made from acrylic materials, it is nevertheless cosmetically desirable to minimize or eliminate them. An average physiologic temperature is about 37°C. At this temperature in a humid or liquid environment, the materials of the present invention are substantially free of glistenings. It is difficult to quantify what is meant by "substantially free." Nevertheless, in order to provide some frame of reference, "substantially free of glistenings" as used herein generally means that the materials have an average of no more than approximately 1 - 2 glistenings per mm² when evaluated in the test described below. Generally, the average number of glistenings per mm² will be much less than 1.

The presence of glistenings is measured by placement of a lens sample in a test chamber with glass slides on the top and bottom for visualization and filled with deionized water. The chamber is placed in a water bath at 37 ± 1 °C for 7 ± 1 days and 14 ± 2 days for visualization. The chamber is then placed on a heated microscope stage at 37 ± 1 °C and visualized with transmitted light at 40 to 200 times magnification.

IOLs constructed of the materials of the present invention can be of any design capable of being rolled or folded into a small cross section that can fit through a relatively smaller incision. For example, the IOLs can be of what is known as a one piece or multipiece design, and comprise optic and haptic components. The optic is that portion which serves as the lens and the haptics are attached to the optic and are like arms which hold the optic in its proper place in the eye. The optic and haptic(s) can be of the same or different material. A multipiece lens is so called because the optic and the haptic(s) are made separately and then the haptics are attached to the optic. In a single piece lens, the optic and the haptics are formed out of one piece of material. Depending on the material, the haptics are then cut, or lathed, out of the material to produce the IOL.

In addition to IOLs, the materials of the present invention are also suitable for use as other ophthalmic devices such as contact lenses, keratoprotheses, and corneal inlays or rings.

The invention will be further illustrated by the following examples which are intended to be illustrative, but not limiting.

Examples 1-8, shown below in Table 1, are illustrative of the materials of the present invention. Each of the formulations of Examples 1 - 8 are prepared as follows, with all of the reactive monomers used being substantially free of inhibitors. After combining the formulation components as listed in Table 1, each formulation is mixed by agitation, purified by passing it through a $0.2\mu\text{m}$ polytetrafluoroethylene filter, and then injected into a polypropylene intraocular lens or a $25 \times 12 \times 1$ mm slab mold as follows.

The bottom portion of the IOL mold contains a cavity which is filled to capacity, and then the top portion of the IOL mold is placed on the bottom portion and locked in place by mating male and female grooves machined into each portion. To make slabs, the cavity in the bottom portion of the slab mold is filled to capacity with the formulation and then the top is placed on strictly as a seal. The molds can either be filled under an inert nitrogen, or standard laboratory atmosphere. To maintain the mold geometry during curing, a means of clamping via springs is asserted on the molds. The clamped molds are placed in a convection air oven and cured using the curing profiles listed in Table 1. At the end of polymerization period, the molds are opened and the cured intraocular lenses or polymer slabs are removed and extracted in acetone to remove any unreacted materials.

The physical properties of the cured materials shown in Table 1 are then assessed (according to the protocols referred to above) using either the lenses or slabs as appropriate for each testing protocol. All of the formulation examples listed are substantially free of vacuoles.

Table 1

EXAMPLES								
COMPONENT	1	2	3	4	5	6	7	8
HEA				30	35			
HEMA						9.8	11.8	14.7
PEA				63.5	58.5	83.5	81.5	78.6
PEMA			63.1					
4-PBMA	84	87.6						
PEO	9.6							
PEGMEMA			29.1					
BDDA			3.1	5	5	3.1	3.1	3.1
OMTP	0.6	1	1.7	0.5	0.5	1.8	1.8	1.8
AMA	2.9							
TEGDA		1.5						
DDDA								
GMMA		7.2						
PI6						1.8	1.8	1.8
LBPO				1	1			
BP	2.9	2.7	2.9					
Cure	2hrs/80°C + 3hrs/100°C	2hrs/80°C + 3hrs/100°C	2hrs/80°C + 3hrs/100°C	1HR/35c- 1HR/50c- 2HR/100c	1HR/35c- 1HR/50c- 2HR/100c	25C to 70C in 10 min, hold 7 hrs, ramp to 100C in 30 min, hold 7 hrs	25C to 70C in 10 min, hold 7 hrs, ramp to 100C in 30 min, hold 7 hrs	25C to 70C in 10 min, hold 7 hrs, ramp to 100C in 30 min, hold 7 hrs
Tg	8.5	15.1	10.7	0	0	10	10	11
Stress	1276	1439	1320	724	681	982	1000	1230
% Strain	461	246	343	392	392	640	610	610
Modulus	362	1250	623	91	89	97	141	212
R.I. (dry)	1.5378	1.5409	1.5337	1.529	1.526	1.544	1.544	1.543
R.I. (wet)	1.5295					1.544	1.543	1.540

	HEA	= 2-Hydroxyethyl acrylate
	HEMA	= 2-Hydroxyethyl methacrylate
	PEA	= 2-Phenylethyl acrylate
5	PEMA	= 2-Phenylethyl methacrylate
	4-PBMA	= 4-Phenylbutyl Methacrylate
	AMA	= Allyl Methacrylate
	PEO	= Polyethylene oxide:1000 Dimethacrylate
	oMTP	= o-methallyl Tinuvin P
10	BP	= Benzoyl peroxide
	DDDA	= 1,12-Dodecanediol Diacrylate
	GMMA	= 2,3-Dihydroxypropyl Methacrylate
	TEGDA	= Triethyleneglycol Diacrylate
	BDDA	= 1,4-Butanediol Diacrylate
15	PEGMEMA	= Polyethylene oxide:200 monomethyl ether monomethacrylate
	tBPO	= t-Butyl (peroxy-2-ethyl) hexanoate
	P16	= Di-(4-t-butylcyclohexyl) peroxydicarbonate

Example 9: Synthesis of the hydrophilic monomer 2-hydroxy-3-phenoxy propylacrylate.

1,2 epoxy-3-phenoxypropane (50 g), acrylic acid (48 g, 100 % excess), 1,4-benzoquinone (0.082 g), and tetramethylammonium bromide (1.8 g) are placed into a flask and heated under agitation for two hours at 110-120 °C. Following reaction, the volatiles were vacuum distilled off at 0.1-0.2 mm Hg at 100 °C. The crude product was then distilled at 170-175 °C pot temperature. The monomer was dissolved in MeCl and washed with 1 % NaOH followed by a water wash. The solution was then dried over anhydrous MgSO₄, filtered through #4 paper, and the solvent stripped on rot-o-vap at 50°C.

Example 10: Synthesis of the hydrophilic monomer 2-pyrrolidone-N-2-ethyl acrylate.

Step 1 - Synthesis of N-(2-hydroxyethyl)-2-pyrrolidone (NHEP): To a 250 ml flask equipped with slanted condenser and condensate receptacle, 107.7 g of 2-aminoethanol and 126.6 g of butyrolactone were added. After several minutes at room temperature there was a vigorous exothermic reaction that peaked at 115 °C. Following the exotherm, the flask was placed into a silicone oil bath at 195-200 °C for 22.5 hours and distillate (mostly water) was collected. The product was then put under high vacuum (0.1 to 0.15 mm Hg) at 115-150 °C to strip off volatiles. The temperature was then increased to 170-190 °C and the product (NHEP) distilled.


Step 2 - Synthesis of 2-Pyrrolidone-N-2-ethylacrylate (NEAP): Into a 500 ml 63-neck flask equipped with slanted condenser and condensate receptacle was placed 71 g of the NHEP along with 125 g methyl acrylate, 4.1 g phenothiazine, and 2.4 g tetra-butyl titanate. The flask, with contents, was placed into a silicone oil bath at 105-108 °C and the methyl acrylate-methanol azeotrope collected. The pot was under continuous agitation. After 21 hours of reaction, the methyl acrylate-methanol was stripped off under rot-o-vap at 65 °C and 120 g of fresh methyl acrylate added to the flask contents and the reaction continued for a total reaction time of 48 hours. The methyl acrylate-methanol was again stripped off under rot-o-vap (as above). The crude NEAP was then placed under high

vacuum at 65 °C to strip off residual methyl acrylate-methanol. The product was distilled (direct take-over) at 140-150 °C at 0.1 mm Hg.

Step 3 - Final Purification: 50 g of A941-500 basic alumina activity-I [60-325
5 mesh] placed in a column and flushed with benzene. The NEAP distillate was diluted
50% parts by weight with benzene, and put onto the column - followed by more benzene.
A total of 412 grams of eluate was collected and the benzene was stripped off under
rotovap at 60 °C, followed by high vacuum at 22 °C for 30 minutes. Sufficient deionized
water was then added to the NEAP to make a 30 percent solution of the monomer; most of
10 the phenothiazine then precipitates out. The solution was then filtered and then extracted
with three 100 ml portions of ether to remove traces of phenothiazine. The water was then
evaporated over high velocity air at room temperature followed by high vacuum at room
temperature for two hours.

We claim:

1. A copolymer having an elongation of at least 150%, comprising a total of at least 90 % by weight of two principal monomers, wherein one principal monomer is an aryl acrylic hydrophobic monomer of the formula



wherein: X is H or CH₃;

m is 0-6;

Y is nothing, O, S, or NR wherein R is H, CH₃, C_nH_{2n+1} (n=1-10) iso-OC₃H₇, C₆H₅, or CH₂C₆H₅; and

Ar is any aromatic ring which can be unsubstituted or substituted with H, CH₃, C₂H₅, n-C₃H₇, iso-C₃H₇, OCH₃, C₆H₁₁, Cl, Br, C₆H₅, or CH₂C₆H₅;

the homopolymer of which has an equilibrium water content of 3 % or less,

and the other principal monomer, present in an amount not greater than the amount of the aryl acrylic hydrophobic monomer, is a hydrophilic monomer having at least one reactive unsaturated functional group, the homopolymer of which has an equilibrium water content of at least 10 %,


and wherein the copolymer further comprises a cross-linking monomer having a plurality of polymerizable ethylenically unsaturated groups.

2. The copolymer of claim 1 wherein m is 2 - 4, Y is nothing or O, and Ar is phenyl.
3. The copolymer of Claim 2 wherein the aryl acrylic hydrophobic monomer is selected from the group consisting of 2-phenylethyl acrylate and 4-phenylbutyl methacrylate.

4. The copolymer of Claim 1 wherein the unsaturated functional group in the hydrophilic monomer is selected from the group consisting of vinyl, acrylate and methacrylate groups.
5. The copolymer of Claim 4 wherein the hydrophilic monomer is selected from the group consisting of 2-hydroxyethyl acrylate; 2-hydroxyethyl methacrylate; 2-N-ethylacrylate pyrrolidone; 2-hydroxy-3-phenoxypropyl acrylate; 2,3-dihydroxypropyl methacrylate; 2-N-vinyl pyrrolidone; polyethylene oxide:200 monomethyl ether monomethacrylate; polyethylene oxide:200 monomethacrylate; and polyethylene oxide:1000 dimethacrylate.
6. The copolymer of Claim 5 wherein the hydrophilic monomer is selected from the group consisting of 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate, and polyethylene oxide:1000 dimethacrylate.
7. The copolymer of Claim 1 further comprising one or more components selected from the group consisting of polymerization initiators, reactive UV absorbers, and reactive blue-light absorbers.
8. The copolymer of Claim 1 wherein the copolymer has a refractive index of at least 1.50.
9. The copolymer of Claim 1 wherein the copolymer has a Tg from about -20 to +25 °C.
10. The copolymer of Claim 9 wherein the copolymer has a Tg from about -5 to +16 °C.
11. The copolymer of Claim 1 wherein the copolymer has an elongation of at least 200%.
12. The copolymer of Claim 11 wherein the copolymer has an elongation from 300 to 600%.

13. The copolymer of Claim 8 wherein the copolymer has a Tg from about -5 to +16 °C and an elongation from 300 to 600 %.

5 14. An ophthalmic lens comprising a copolymer having an elongation of at least 150%, comprising a total of at least 90 % by weight of two principal monomers, wherein one principal monomer is an aryl acrylic hydrophobic monomer of the formula



wherein: X is H or CH₃;

15 m is 0-6;

Y is nothing, O, S, or NR wherein R is H, CH₃, C_nH_{2n+1} (n=1-10) iso-

OC₃H₇, C₆H₅, or CH₂C₆H₅; and

Ar is any aromatic ring which can be unsubstituted or substituted with

H, CH₃, C₂H₅, n-C₃H₇, iso-C₃H₇, OCH₃, C₆H₁₁, Cl, Br, C₆H₅,

20 or CH₂C₆H₅;

the homopolymer of which has an equilibrium water content of 3 % or less,

25 and the other principal monomer, present in an amount not greater than the amount of the aryl acrylic hydrophobic monomer, is a hydrophilic monomer having at least one reactive unsaturated functional group, the homopolymer of which has an equilibrium water content of at least 10 %,

30 and wherein the copolymer further comprises a cross-linking monomer having a plurality of polymerizable ethylenically unsaturated groups.

15. The ophthalmic lens of Claim 14 wherein the lens is an intraocular lens.

16. The intraocular lens of Claim 15 wherein m is 2 - 4, Y is nothing or O, and Ar is phenyl.
- 5 17. The intraocular lens of Claim 16 wherein the aryl acrylic hydrophobic monomer is selected from the group consisting of 2-phenylethyl acrylate and 4-phenylbutyl methacrylate.
18. The intraocular lens of Claim 16 wherein the unsaturated functional group in the
10 hydrophilic monomer is selected from the group consisting of vinyl, acrylate, and methacrylate groups.
19. The intraocular lens of Claim 18 wherein the hydrophilic monomer is selected from
15 the group consisting of 2-hydroxyethyl acrylate; 2-hydroxyethyl methacrylate; 2-N-ethylacrylate pyrrolidone; 2-hydroxy-3-phenoxypropyl acrylate; 2,3-dihydroxypropyl methacrylate; 2-N-vinyl pyrrolidone; polyethylene oxide:200 monomethyl ether monomethacrylate; polyethylene oxide:200 monomethacrylate; and polyethylene oxide:1000 dimethacrylate.
- 20 20. The intraocular lens of Claim 19 wherein the hydrophilic monomer is selected from the group consisting of 2-hydroxyethyl acrylate, 2-hydroxyethyl methacrylate, and polyethylene oxide:1000 dimethacrylate.
21. The intraocular lens of Claim 15 further comprising one or more components
25 selected from the group consisting of polymerization initiators, reactive UV absorbers, and reactive blue-light absorbers.
22. The intraocular lens of Claim 21 wherein the polymerization initiator is a peroxy free-radical initiator.
- 30 23. The intraocular lens of Claim 22 wherein the reactive UV absorber is 2-(2'-hydroxy-3'-methallyl-5'-methylphenyl)benzotriazole.

24. The intraocular lens of Claim 15 wherein the intraocular lens has a refractive index of at least 1.50.
- 5 25. The intraocular lens of Claim 15 wherein the intraocular lens has a Tg from about -20 to +25 °C.
26. The intraocular lens of Claim 25 wherein the intraocular lens has a Tg from about -5 to +16 °C.
- 10 27. The intraocular lens of Claim 15 wherein the intraocular lens has an elongation of at least 200%.
28. The intraocular lens of Claim 27 wherein the intraocular lens has an elongation from
15 300 to 600%.
29. An intraocular lens having an optic comprising 2-phenylethyl acrylate in an amount of about 80 % by weight, 2-hydroxyethyl methacrylate in an amount of about 15 % by weight, a cross-linking monomer, a UV-absorber and a polymerization initiator.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/06743

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61L27/00 C08F220/30 G02B1/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61L C08F G02B		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A,5 290 892 (NAMDARAN FARHAD H ET AL) 1 March 1994 cited in the application see claims 1-8 see column 3, line 32 - line 61 ---	1-20
Y	EP,A,0 485 197 (NESTLE SA) 13 May 1992 see claims 1-15 ---	1-20
Y	US,A,5 331 073 (WEINSCHENK III JOSEPH I ET AL) 19 July 1994 cited in the application see claims 1-22 see column 3, line 45 - line 51 see column 4, line 36 - line 56 see column 5, line 32 - line 49 see column 9; example 2 ---	1-20
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 9 August 1996		Date of mailing of the international search report 26.08.96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer Depijper, R

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 96/06743

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,96 11235 (PHARMACIA AB ;HODD KENN (NL)) 18 April 1996 see claims 1-7 see page 4, line 20 - line 29 ---	1
A	WO,A,95 11279 (ALCON LAB INC) 27 April 1995 see claims 3,7 see page 1, paragraph 2 see page 12, paragraph 5 - page 13, paragraph 1 ---	1
A	US,A,4 260 954 (CROOKS ROBERT C) 7 April 1981 see claims 1-13 ---	1
A	US,A,4 036 814 (HOWES JOHN GORDON BERNARD ET AL) 19 July 1977 see claims 1,6-8,17 see column 2, line 3 - line 18 -----	1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 96/06743

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5290892	01-03-94	US-A- 5403901	04-04-95
		US-A- 5433746	18-07-95
		AU-B- 652389	25-08-94
		AU-B- 8705091	14-05-92
		CA-A- 2055138	08-05-92
		EP-A- 0485197	13-05-92
		JP-A- 4292609	16-10-92
EP-A-0485197	13-05-92	AU-B- 652389	25-08-94
		AU-B- 8705091	14-05-92
		CA-A- 2055138	08-05-92
		JP-A- 4292609	16-10-92
		US-A- 5290892	01-03-94
		US-A- 5403901	04-04-95
		US-A- 5433746	18-07-95
US-A-5331073	19-07-94	AU-B- 5549794	08-06-94
		EP-A- 0667966	23-08-95
		JP-T- 8503506	16-04-96
		WO-A- 9411764	26-05-94
		US-A- 5359021	25-10-94
WO-A-9611235	18-04-96	AU-B- 3692195	02-05-96
WO-A-9511279	27-04-95	US-A- 5470932	28-11-95
		AU-B- 8014794	08-05-95
		CA-A- 2147856	27-04-95
		EP-A- 0674684	04-10-95
		JP-T- 8503997	30-04-96
		US-A- 5528322	18-06-96
US-A-4260954	07-04-81	CA-A- 1133595	12-10-82
		DE-A- 3002487	31-07-80
		FR-A- 2449365	12-09-80
		GB-A, B 2040634	28-08-80
		JP-A- 55100799	31-07-80
		NL-A- 8000476	29-07-80
US-A-4036814	19-07-77	GB-A- 1494641	07-12-77
		AR-A- 207867	08-11-76

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/US 96/06743

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4036814		AT-B- 349789	25-04-79
		AU-B- 8272275	06-01-77
		CA-A- 1037196	22-08-78
		CH-A- 603708	31-08-78
		DE-A- 2529639	22-01-76
		FR-A, B 2277110	30-01-76
		JP-C- 1210731	12-06-84
		JP-A- 51030750	16-03-76
		JP-B- 58045689	12-10-83
		NL-A- 7507914	06-01-76
		SE-B- 407416	26-03-79
		SE-A- 7507693	05-01-76
		BE-A- 831047	05-01-76

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61L 27/00, C08F 220/30, G02B 1/04		A1	(11) International Publication Number: WO 96/40303
			(43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: PCT/US96/06743		(81) Designated States: AU, CA, CN, JP, KR, MX, SG, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 10 May 1996 (10.05.96)			
(30) Priority Data: 08/486,557 7 June 1995 (07.06.95) US		Published <i>With a revised version of the international search report.</i>	
(71) Applicant: ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Fort Worth, TX 76134-2099 (US).		(88) Date of publication of the revised version of the international search report: 9 May 1997 (09.05.97)	
(72) Inventors: FREEMAN, Charles; 725 Windridge Lane, Burleson, TX 76028 (US). JINKERSON, David, L.; 125 Berkshire Lane, Forth Worth, TX 76134 (US). KARAKELLE, Mutlu; 6713 Glen Meadow Drive, Fort Worth, TX 76132 (US). LeBOEUF, Albert, R.; 7861 Mahonia Drive, Fort Worth, TX 76133 (US).			
(74) Agents: RYAN, Patrick, M. et al.; Alcon Laboratories, Inc., Patent Dept. Q-148, 6201 South Freeway, Forth Worth, TX 76134-2099 (US).			
(54) Title: IMPROVED HIGH REFRACTIVE INDEX OPHTHALMIC LENS MATERIALS			
(57) Abstract			
Disclosed are improved soft, high refractive index, acrylic materials having an elongation of at least 150 %. These materials, especially useful as intraocular lens materials, contain two principal monomers: an aryl acrylic hydrophobic monomer and a hydrophilic monomer.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L27/00 C08F220/30 G02B1/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L C08F G02B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A,5 290 892 (NAMDARAN FARHAD H ET AL) 1 March 1994 cited in the application see claims 1-8 see column 3, line 32 - line 61 ---	1-20
Y	EP,A,0 485 197 (NESTLE SA) 13 May 1992 see claims 1-15 ---	1-20
Y	US,A,5 331 073 (WEINSCHENK III JOSEPH I ET AL) 19 July 1994 cited in the application see claims 1-22 see column 3, line 45 - line 51 see column 4, line 36 - line 56 see column 5, line 32 - line 49 see column 9; example 2 ---	1-20
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *A* document member of the same patent family

Date of the actual completion of the international search

9 August 1996

Date of mailing of the international search report

28.02.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

DEPIJPER R.D.C.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/06743

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,96 11235 (PHARMACIA AB ;HODD KENN (NL)) 18 April 1996 see claims 1-7 see page 4, line 20 - line 29 ---	1
A	WO,A,95 11279 (ALCON LAB INC) 27 April 1995 see claims 3,7 see page 1, paragraph 2 see page 12, paragraph 5 - page 13, paragraph 1 ---	1
A	US,A,4 620 954 (HELMUT SINGER) 4 November 1986 see claims 1-13 ---	1
A	US,A,4 036 814 (HOWES JOHN GORDON BERNARD ET AL) 19 July 1977 see claims 1,6-8,17 see column 2, line 3 - line 18 -----	1

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/06743

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5290892 A	01-03-94	US 5403901 A	04-04-95
		US 5433746 A	18-07-95
		AT 143677 T	15-10-96
		AU 652389 B	25-08-94
		AU 8705091 A	14-05-92
		CA 2055138 A	08-05-92
		DE 69122471 D	07-11-96
		DE 69122471 T	06-02-97
		EP 0485197 A	13-05-92
		ES 2094796 T	01-02-97
		JP 4292609 A	16-10-92
EP 0485197 A	13-05-92	AT 143677 T	15-10-96
		AU 652389 B	25-08-94
		AU 8705091 A	14-05-92
		CA 2055138 A	08-05-92
		DE 69122471 D	07-11-96
		DE 69122471 T	06-02-97
		ES 2094796 T	01-02-97
		JP 4292609 A	16-10-92
		US 5290892 A	01-03-94
		US 5403901 A	04-04-95
		US 5433746 A	18-07-95
US 5331073 A	19-07-94	AU 5549794 A	08-06-94
		EP 0667966 A	23-08-95
		JP 8503506 T	16-04-96
		WO 9411764 A	26-05-94
		US 5359021 A	25-10-94
WO 9611235 A	18-04-96	AU 3692195 A	02-05-96
WO 9511279 A	27-04-95	US 5470932 A	28-11-95
		AU 674262 B	12-12-96
		AU 8014794 A	08-05-95
		CA 2147856 A	27-04-95
		EP 0674684 A	04-10-95
		JP 8503997 T	30-04-96
		US 5543504 A	06-08-96
		US 5528322 A	18-06-96

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 96/06743

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4620954 A	04-11-86	NONE	

US 4036814 A	19-07-77	GB 1494641 A	07-12-77
		AR 207867 A	08-11-76
		AT 349789 B	25-04-79
		AU 8272275 A	06-01-77
		BR 7504239 A	06-07-76
		CA 1037196 A	22-08-78
		CH 603708 A	31-08-78
		DE 2529639 A	22-01-76
		FR 2277110 A	30-01-76
		JP 1210731 C	12-06-84
		JP 51030750 A	16-03-76
		JP 58045689 B	12-10-83
		NL 7507914 A	06-01-76
		SE 407416 B	26-03-79
		SE 7507693 A	05-01-76
		BE 831047 A	05-01-76

<p>99-204996/17 A96 D22 (A14 A60) MUEL/ 97.09.02 MUELLER-LIERHEIM W G K *WO 9911303-A1 97.09.02 97DE-1038345 (99.03.11) A61L 27/00 Flexible intraocular lens, optionally with more rigid haptic (Ger) C99-059679 N(AU BA BG BR CA CN CZ EE GE HU ID IL JP KP KR MX NO NZ PL SG SK TR TT UA US UZ VN YU) R(AT BE CH CY DE DK EA ES FI FR GB GR IE IT LU MC NL PT SE) Addnl. Data: MUELLER-LIERHEIM W G K 98.09.01 98WO-EP05540</p>	<p>A(4-F6E5, 8-C7, 12-V2A) D(9-C1A)</p>
<p>NOVELTY Flexible intraocular lens is made from a copolymer (I) of ≤ 80 wt.% hydroxyethyl methacrylate (HEMA) with 4-17 wt.% methyl methacrylate (MMA) or ethyl methacrylate, strongly crosslinked to a 3-dimensional network with ethylene glycol dimethacrylate (EGDMA).</p> <p>DETAILED DESCRIPTION An INDEPENDENT CLAIM is also included for an intraocular lens with a flexible optical lens and more rigid haptic part.</p> <p>USE</p>	<p>The optical lenses are used as intraocular lenses.</p> <p>ADVANTAGE The lenses have satisfactory long-term stability towards hydrolysis, especially in the biological medium of the eye, whereas existing lenses of this type, that are not strongly crosslinked, have inadequate stability.</p> <p>SPECIFIC COMPOUNDS A specific example of a UV absorber is 4-methacryloxy-2-hydroxybenzophenone.</p> <p>EXAMPLE A mixture suitable for making a haptic ring contained 94.79 wt.% MMA or ethyl methacrylate, 5.00 wt.% EGDMA, 0.20 wt.% azo-bis-isobutyronitrile (AIBN) and 0.01 wt.% Solvent Green 3. A mixture suitable for making the optical part or as lens material contained 89.70 wt.% HEMA, 8.00 wt.% MMA or ethyl methacrylate, 2.00 wt.% EGDMA, 0.25 wt.% 4-methacryloxy-2-hydroxybenzophenone and</p> <p>WO 9911303-A+</p>

<p>0.05 wt.% AIBN.</p> <p>TECHNOLOGY FOCUS Polymers - Preferred Lens: The lens has an optical part of (I) and a haptic part of poly(m)ethyl methacrylate (IIA) or a MMA-ethyl methacrylate copolymer (IIB), optionally containing a smaller amounts of HEMA, both parts being strongly crosslinked with EGDMA. Preferred Polymers: (I) contains up to 95 wt.% HEMA. An ultraviolet (UV) absorber containing functional reactive group(s), especially $=CH_2$, may be polymerized in the copolymer matrix of the optical lens. The 2-part lens is made from a blank by polymerizing (I) in a ring of (IIA) or (IIB), which preferably is pre-swollen. In particular, the (m)ethyl methacrylate is diffused into the ring from the solution for polymerization to the optical part, before this is polymerized. The lens is steam-sterilized. (16pp0016DwgNo.0/0)</p>	<p>WO 9911303-A</p>
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------

THIS PAGE BLANK (USPTO)